OrthoSpineNews

SEPTEMBER 24, 2024

NEW YORK, September 24, 2024 –(BUSINESS WIRE)– Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced the completion of enrollment of its U.S. Phase 3 clinical trial of SB-01 For Injection (SB-01).

Degenerative Disc Disease 94

Degenerative Disc Disease Spine Clinic 94

OrthoSpineNews

OCTOBER 8, 2024

Advancements and Projections in the Global Degenerative Disc Disease Treatment Market: Insights, Trends, Opportunities, and Recent Developments New York, Oct. 08, 2024 (GLOBE NEWSWIRE) — Overview – The Global Degenerative Disc Disease Treatment Market is projected to reach USD 34.0

Degenerative Disc Disease 52

Degenerative Disc Disease Treatment Spine 52

OrthoSpineNews

JULY 16, 2024

Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 16, 2024 /PRNewswire/ — DiscGenics, Inc.,

Degenerative Disc Disease 52

Degenerative Disc Disease Clinic Musculoskeletal Spine 52

OrthoSpineNews

SEPTEMBER 27, 2024

27, 2024 (GLOBE NEWSWIRE) — 33 Medical, Inc., a leader in cutting-edge spinal health innovations, is proud to announce that its NuvoDisc® medical device has been awarded the prestigious 2024 Best Technology in Spine Award. Boca Raton, FL, Sept.

Degenerative Disc Disease 52

Degenerative Disc Disease Spine Treatment Health 52

OrthoSpineNews

JULY 11, 2024

July 11, 2024 /PRNewswire/ — Providence Medical Technology announces FDA Clearance of its CORUS™ Posterior Cervical Stabilization System (PCSS) for the treatment of up to 3-level cervical Degenerative Disc Disease (DDD).

Degenerative Disc Disease 52

Degenerative Disc Disease Clinic Spine Treatment 52

OrthoSpineNews

MAY 6, 2025

Global Spine and VCF Market by Segment 2024 – 2031 – iData Research (CNW Group/iData Research Inc.) billionin 2024 to nearly$32 billionby 2031, alongside the minimally invasive spinal (MIS) implant market’s rise from$4 billionin 2024 to nearly$6 billionby 2031.

Degenerative Disc Disease 52

Degenerative Disc Disease Spine Health Patients 52

OrthoSpineNews

MAY 14, 2025

First quarter 2025 deferred revenues were $150,000, compared to $nil in the first quarter of 2024. million for the comparable period of 2024. per share, for the first quarter of 2024. per share, for the first quarter of 2024. The change was primarily due to a gain on the exchange of warrants in Q1-2024.

Degenerative Disc Disease 52

Degenerative Disc Disease Lower Back Pain Neck Pain Treatment 52